// App-Quantinova.ai

: Synergistic Activity of the MCL-1-Specific Inhibitor S63845 with Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Felix Seyfried

Principal Investigators

  • Felix Stirnwei

  • Stefan Khrer

  • Klaus-Michael Debatin

  • Lder Hinrich Meyer

Medical Centers

  • Department of Pediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany,

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Solid malignancies

Biomarkers

  • BCL2 associated X, apoptosis regulator

  • BCL2 like 11

  • Nucleoside diphosphate kinase A

  • Histone-lysine N-methyltransferase 2A

Drug/Treatment

  • Venetoclax

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved